...
首页> 外文期刊>European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology >The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma.
【24h】

The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma.

机译:胃癌患者血管内皮生长因子(VEGF)-C和VEGF受体3的表达对临床结局的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AIMS: We aimed to investigate the relationship among VEGF-C/VEGFR-3 expression, lymphatic metastasis and patient prognosis in gastric carcinoma. MATERIAL AND METHODS: VEGF-C and VEGFR-3 expression in gastric carcinoma tissues obtained from 204 patients who underwent curative gastrectomy (105 cases presented with lymph node metastasis and 99 cases without metastasis) was examined immunohistochemically. There was no significant difference in the other clinicopathologic variables except for postoperative pathological tumor stage (pT) and TNM stage between the two groups. The results were statistically processed. RESULTS: The results showed that VEGF-C was located mainly in the cytoplasm of tumor cells and VEGFR-3 was found predominantly in the endothelium of lymphatic vessels. VEGF-C and VEGFR-3 expression was more frequent in gastric carcinoma tissues than that in normal gastric tissues, 54.90% and 35.29% respectively, which revealed that the expression of VEGF-C and VEGFR-3 was significantly stronger in patients with lymph node metastasis than in those without metastasis. Patients who had positive staining for VEGF-C showed significantly less favorable survival rates compared with patients who had negative staining for VEGF-C. The survival rates of patients who had positive staining for VEGFR-3 also were significantly lower compared with patients who had negative staining for VEGFR-3. Patients who had positive staining for both VEGF-C and VEGFR-3 exhibited the most unfavorable prognosis. Multivariate analysis demonstrated that the expression of VEGF-C and VEGFR-3 was an independent prognostic determinant. In addition, faint to moderate VEGF-C expression was detected in normal gastric epithelial cells (18/204, 8.9%). CONCLUSIONS: VEGF-C and VEGFR-3 expression could serve as a prognostic biomarker in patients with gastric carcinoma.
机译:目的:我们旨在研究胃癌中VEGF-C / VEGFR-3表达,淋巴结转移与患者预后之间的关系。材料与方法:对204例行根治性胃切除术(105例有淋巴结转移和99例无转移)的胃癌组织中VEGF-C和VEGFR-3的表达进行了免疫组织化学检查。两组之间除术后病理肿瘤分期(pT)和TNM分期外,其他临床病理变量无显着差异。对结果进行统计处理。结果:VEGF-C主要位于肿瘤细胞的细胞质中,VEGFR-3主要位于淋巴管的内皮中。胃癌组织中VEGF-C和VEGFR-3的表达比正常胃组织中更频繁,分别为54.90%和35.29%,这表明在淋巴结患者中VEGF-C和VEGFR-3的表达明显更强。转移要比无转移者高。 VEGF-C染色阳性的患者与VEGF-C染色阴性的患者相比,生存率明显降低。与VEGFR-3染色阴性的患者相比,VEGFR-3染色阳性的患者的生存率也明显降低。 VEGF-C和VEGFR-3染色均阳性的患者预后最差。多因素分析表明,VEGF-C和VEGFR-3的表达是独立的预后决定因素。另外,在正常胃上皮细胞中检测到微弱至中等的VEGF-C表达(18 / 204,8.9%)。结论:VEGF-C和VEGFR-3的表达可作为胃癌患者预后的生物学指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号